Designing Clinical Trials in Wilson's Disease.

Area of Science:

• Genetics and rare diseases
• Clinical trial design
• Neurology and hepatology

Background:

• Wilson disease (WD) is an inherited disorder of copper metabolism due to ATP7B gene mutations.
• Current WD treatments, while effective, have limitations, necessitating new therapeutic strategies.
• Increased clinical trials are expected for developing novel treatment modalities for WD.

Purpose of the Study:

• To establish a consensus on the design of clinical trials for Wilson disease.
• To address key aspects of trial design, including patient populations, comparators, and endpoints.
• To optimize recruitment and data analysis for rare disease research.

Main Methods:

• Consensus reached at the Wilson Disease Aarhus Symposium workshop on randomized clinical trial design.
• Discussion and agreement on trial population criteria, including all clinical phenotypes.
• Consideration of treatment-naive and treatment-experienced patients for broader applicability.

Main Results:

• Recommendations for defining trial populations to ensure adequate patient recruitment for rare diseases.
• Emphasis on using clinical or composite endpoints until validated surrogate markers are available.
• Proposal for standardizing trial designs to facilitate data pooling and comparison.

Conclusions:

• Standardized clinical trial designs are essential for Wilson disease research.
• Pooling data from standardized trials will enable better treatment comparisons.
• Improved trial design can reduce the number of patients required for future studies.